Ajay Nirula
Eli Lilly (United States)(US)Recludix Pharma (United States)(US)
Publications by Year
Research Areas
COVID-19 Clinical Research Studies, SARS-CoV-2 and COVID-19 Research, Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Asthma and respiratory diseases
Most-Cited Works
- → SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19(2020)1,420 cited
- → Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19(2021)941 cited
- → Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis(2015)792 cited
- → A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis(2016)450 cited
- → Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis(2014)390 cited
- → What is IgG4? A review of the biology of a unique immunoglobulin subtype(2010)312 cited
- → Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID ‐19 patients